Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | NMT2 | O60551 | 2/20 | 0.47 |
| ▸ | NMT1 | P30419 | 2/20 | 0.47 |
| ▸ | CHRND | Q07001 | 6/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.46 |
| ▸ | CHRNG | P07510 | 2/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17325767 | 1.00 | SIRT6 (0.48) | SIRT6SIRT1NMT2NMT1CHRND | |
| SCHEMBL20752792 | 0.91 | NMT1 (0.41) | SIRT6SIRT1NMT2NMT1CHRND | |
| SCHEMBL19982268 | 0.90 | NMT2 (0.40) | SIRT6SIRT1NMT2NMT1CHRND | |
| SCHEMBL14704041 | 0.90 | ROCK2 (0.41) | SIRT6SIRT1NMT2NMT1CHRND | |
| SCHEMBL12284049 | 0.89 | GLP1R (0.39) | SIRT6SIRT1NMT2NMT1ROCK2 | |
| SCHEMBL18893551 | 0.86 | SIRT6 (0.50) | SIRT6SIRT1TLR2 | |
| SCHEMBL16152402 | 0.86 | GLP1R (0.41) | NMT2NMT1ROCK2PRKACAAKT3 | |
| SCHEMBL25062575 | 0.86 | SIRT6 (0.53) | SIRT6SIRT1NMT2NMT1CHRND | |
| SCHEMBL19429720 | 0.85 | ALB (0.47) | ROCK2PRKACAAKT3TLR2 | |
| SCHEMBL25062576 | 0.85 | NMT1 (0.48) | SIRT6SIRT1NMT2NMT1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289785-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-09-15 | — | — | US | disclosed |
| US-11117917-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| EP-2844662-B1 | TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | SIRNA THERAPEUTICS INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20190153016-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2019-05-23 | — | — | US | disclosed |
| US-10221205-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| EP-2555777-B1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | SIRNA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2611927-B1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | SIRNA THERAPEUTICS INC (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20180079769-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2018-03-22 | — | — | US | disclosed |
| US-9840531-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170306324-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2017-10-26 | — | — | US | disclosed |
| US-20170137815-A1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | SIRNA THERAPEUTICS INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-20150374844-A1 | NOVEL PH -SWITCHABLE PEPTIDES FOR MEMBRANE INSERTION AND PORE FORMATION | UNIV PENNSYLVANIA (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150246133-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2015-09-03 | — | — | US | disclosed |
| WO-2014126828-A9 | NOVEL PH-SWITCHABLE PEPTIDES FOR MEMBRANE INSERTION AND PORE FORMATION | SIRNA THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2014126828-A1 | NOVEL PH-SWITCHABLE PEPTIDES FOR MEMBRANE INSERTION AND PORE FORMATION | MERCK SHARP & DOHME CORP. (US) | 2014-08-21 | — | — | WO | disclosed |
| WO-2013166155-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2013-11-07 | — | — | WO | disclosed |
| US-20130253168-A1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | SIRNA THERAPEUTICS, INC. | 2013-09-26 | — | — | US | disclosed |
| US-20130041133-A1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2013-02-14 | — | — | US | disclosed |
| WO-2012030683-A2 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-8067005-B1 | Divalent antibody fragments | UCB PHARMA S.A. (BE) | 2011-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246133-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | GALNT3, CSGALNACT1, FUT6 | SIRT6 3028/4885SIRT1 3649/4885NMT2 101/4885 |
| US-20130041133-A1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | PHAX, NSUN3, NSUN2 | SIRT6 3360/4885SIRT1 2614/4885NMT2 2251/4885 |
| US-20190153016-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | GALNT3, CSGALNACT1, FUT6 | SIRT6 3028/4885SIRT1 3649/4885NMT2 101/4885 |
| US-20150374844-A1 | NOVEL PH -SWITCHABLE PEPTIDES FOR MEMBRANE INSERTION AND PORE FORMATION | PSPH, VIP, HM13 | SIRT6 4122/4885SIRT1 4754/4885NMT2 1139/4885 |
| US-20220289785-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | GALNT3, CSGALNACT1, FUT6 | SIRT6 3028/4885SIRT1 3649/4885NMT2 101/4885 |
| US-11117917-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | GALNT3, B3GAT3, CSGALNACT1 | SIRT6 3267/4885SIRT1 3835/4885NMT2 113/4885 |
| US-10221205-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | GALNT3, B3GAT3, CSGALNACT1 | SIRT6 3267/4885SIRT1 3835/4885NMT2 113/4885 |
| US-20180079769-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | GALNT3, CSGALNACT1, FUT6 | SIRT6 3028/4885SIRT1 3649/4885NMT2 101/4885 |
| US-20130253168-A1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | ALKBH1, ADAR, RNGTT | SIRT6 2107/4885SIRT1 1109/4885NMT2 594/4885 |
| US-20170306324-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | GALNT3, CSGALNACT1, FUT6 | SIRT6 3028/4885SIRT1 3649/4885NMT2 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.